Welcome to vnonline.co.uk

vnonline.co.uk provides the veterinary nursing profession with the latest news and industry developments, as well as events, resources, learning materials and careers.

Our website is dedicated to veterinary nurses and we strive to provide a platform where you can voice and explore your interests.

Not a member yet? Sign up for free!

Register for free with vnonline.co.uk to gain unlimited access to news, resources, jobs and much more!



Click here to become a member






Log in to vnonline

Forgot your password?

Posted: 4th October 2016

Earlier treatment 'could delay onset of heart failure'
dog
Lead author Adrian Boswood, professor of veterinary cardiology at the RVC, said thanks to the findings, vets no longer have to adopt a 'watch and wait' approach with suspected preclinical cases of MVD.
RVC: Study highlights need for shift in treatment of preclinical MVD
 
A new study suggests earlier treatment of preclinical mitral valve disease (MVD) can delay the onset of heart failure in dogs. Researchers from the Royal Veterinary College (RVC) say this highlights the need for a shift in the way vets diagnose and manage the disease.

The study, Evaluation of Pimobendan in Cardiomegaly (EPIC), found the drug was able to extend the asymptomatic period by 15 months on average and dogs that received pimobendan lived significantly longer than those receiving a placebo. The findings have been published in the Journal of Veterinary Internal Medicine.

Heart disease is one of the top five causes of death in UK dogs and MVD accounts for 75 per cent of cases.

Lead author Adrian Boswood, professor of veterinary cardiology at the RVC, said thanks to the findings, vets no longer have to adopt a 'watch and wait' approach with suspected preclinical cases of MVD.

"When a typical mitral valve murmur is detected, vets should now investigate further to look for cardiac enlargement. If demonstrated, this suggests the patient will probably benefit from treatment with pimobendan before the onset of clinical signs."

Researchers say the EPIC study, which was designed and run by an independent team and sponsored by Boehringer Ingelheim, is the largest prospective veterinary cardiology study carried out to date and produced data to rival that of human clinical trials. Taking seven years to complete, it involved 360 dogs across 11 countries in four continents.

In light of the findings, the team say vets should now consider testing early for signs of preclinical MVD, and in dogs with cardiomegaly secondary to preclinical MVD, should consider the use of pimobendan to delay the onset of congestive heart failure and extend the asymptomatic period.
 

Image courtesy of RVC




Become a member or log in to add this story to your CPD history



Latest news | Careers | Events | Resources | Contact us | Terms and conditions | Data Protection and Privacy |Cookie policy | About us | Copyright
© 2024 Vision Media, all rights reserved. vnonline.co.uk is not responsible for the content of external websites.